Newly developed faropenem (FRPM) was evaluated clinically and pharmacokinetically in pediatrics as follows. 1. Efficacy The clinical efficacy was determined in 494 cases. The efficacy rate was 91.9% (271/295) in 295 patients from whom the above causal agents were isolated and 93.0% (185/199) in 199 patients without isolation of the agent. The bacteriological eradication rate was 82.5% (250/303 strains). The MICs of FRPM for penicillin resistant Streptococcus pneumoniae (PRSP) were ≤0.025 to 0.2 μg/ml. In all 10 cases, the clinical efficacy was more than good. The bacteriological eradication rate was 6 out of 8. The clinical efgcacy rate for cases which were non-responsive to previous chemotherapy was 89.3% (50/56). 2. Safety Side effects were observed in 6.6% (36/548) of the evaluated cases for safety. These were diarrhea, loose stool, gluteal candidiasis, urticaria and rash. There were abnormal laboratory findings in 37 cases including elevation of eosinophile, GPT, GOT, γ-GTP. None of the side effects or abnormal laboratory findings were serious. 3. Palatability of the drug The palatability of the drug was quite good. It was evaluated as more than moderate by 99.3% (555/559) of the patients. From the above results FRPM is considered to be quite useful in pediatric infections including PRSP infections.
|ジャーナル||Japanese Journal of Chemotherapy|
|出版ステータス||Published - 1997|
ASJC Scopus subject areas